600 patients66,869 observations120 daysLIVE

Patient P-01830

Synthetic patientNBL-101 · Day 120 · 25–34 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 49 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days
  • Treatment adherence+13
  • GI instability+6
  • Inflammatory activity-3
  • Nutritional resilience-2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    92%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 84% showed improvement
    • median effect visible after 8 days

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    69.2/100
    stable · +2.0 vs previous 14 d
    Toxicity
    Blood
    51.3/100
    stable · +0.5 vs previous 14 d
    Sleep quality
    Wearable
    9.4/100
    worsening · -4.4 vs previous 14 d
    Energy level
    Daily log
    1.1/10
    stable · -0.0 vs previous 14 d
    Stress level
    Daily log
    6.7/10
    stable · -0.0 vs previous 14 d
    Steps
    Wearable
    7,058
    improving · +565 vs previous 14 d
    Adherence
    Companion
    49.5 %
    worsening · -2.6 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards restoration · 21 from the failing basin, 74 from restoration.

    Would help
    • GI-04 GI Support Protocol
      73% improved among 123 similar · onset 8 d · confidence 96%
    • ME-01 Monitoring Escalation
      100% improved among 78 similar · onset 3 d · confidence 70%
    • NP-02 Dietary Support Protocol
      63% improved among 64 similar · onset 10 d · confidence 70%
    Would not help
    • Keep fat low
      GI +3 next day on high-intake days · n 20
    • Keep simple carbs low
      GI +2.6 next day on high-intake days · n 20
    • Keep histamine low
      GI +2.2 next day on high-intake days · n 23
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Dietary fat load
      +3detractor · 95%
    • Simple carbohydrates
      +2.6detractor · 95%
    • Histamine load
      +2.2detractor · 86%
    • Spicy / capsaicin
      +1no signal · 31%
    • Alcohol
      -0.9no signal · 27%
    • Insoluble fibre
      +0.2no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 90
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • MicrobiomeAkkermansia low → thinner mucus layer
      • Daily logGI symptom score 69 and rising
      • WearableSleep 5.0 h, below personal baseline
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 30/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Drug metabolism and exposure 60
      • DNACYP2D6 poor metabolizer → higher exposure
      • BloodToxicity index 51
    • Inflammatory signalling 50
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 63
    • Autonomic recovery 45
      • WearableResting HR 84 bpm
      • WearableShort sleep window
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 2.5 · butyrate capacity 30/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    40 ms
    Sleep
    4.8 h
    Steps
    6,343
    Resting HR
    82 bpm
    Daily log: GI score 69, nutritional resilience 37, adherence 50.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0181347%S01NP-02no change40
    P-0132737%S01GI-04improved56
    P-0131028%S0157
    P-0168828%S01GI-04improved40
    P-0187723%S01CR-01improved67
    P-0182119%S0158
    P-0160418%S0171
    P-0169518%S0130
    P-0173118%S01ME-01improved32
    P-0163531%S02GI-04improved49
    P-0145230%S02GI-04improved46
    P-0145925%S0251